Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Datamonitor Reports | Stakeholder Opinions: Renal Anemia Early diagnosis and management of anemia: reducing costs and improving the outcomes in chronic kidney disease

Stakeholder Opinions: Renal Anemia Early diagnosis and management of anemia: reducing costs and improving the outcomes in chronic kidney disease

The diagnosis of renal anemia is routinely performed and relatively straightforward, while treatment with highly effective erythropoietin-stimulating agents is widely available in all major markets. However, the extremely high cost of treatment prevents many healthcare providers from delivering this treatment to all eligible patients.

What are the current definitions, pathophysiological stages and the classification of renal anemia?

What are the currently available diagnostic methods, the issues and the unmet needs in diagnosis and early detection of renal anemia?

What is the current state of pharmacological management, available treatment approaches in renal anemia, unmet needs and future trends?

What are the current issues and the commercial landscape of renal anemia marketplace?

In Europe, biogeneric epoetins were expected to address the cost issue, however, so far they have not been particularly well received. This seems to be mostly due to physician conservatism and the fear of poor generic drug quality with attendant higher risk of side effects. Only Germany has displayed any degree of enthusiasm for biogenerics.

A number of large clinical trials, such as CHOIR and CREATE, have demonstrated some controversial results with regards to the relative inefficiency of higher hemoglobin targets. This has encouraged healthcare providers to be conservative in the choice of epoetin therapy creating an additional barrier to epoetin revenue growth.

New epoetin drug therapies predominantly address the length of drug action, allowing for less frequent administration, but unfortunately they provide neither substantial superiority nor significant reduction of costs. In addition, a very small upcoming pipeline does not yet promise any advancement in the area of superiority or reduction of cost.

Understand current definitions, diagnostic methods and treatment approaches in renal anemia

Current challenges and future opportunities in renal anemia management

Differences, advantages and disadvantages of pharmacological disease management

Publication: 39904
Library Code: DMHC2501
Type: Report
Format: PDF & SlidePack
Pages: 83

Table of Contents
Price: $3,800.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions